Background/Aims: Loss of endothelial barrier function plays an important role in the development of ventilator-induced lung injury (VILI). This study aimed to investigate the effects of miR135a on VILI in a model of mechanical stretch (MS)-induced human umbilical vein endothelial cell (HUVEC) injury. Methods: HUVECs were randomly assigned to 7 groups: blank, negative control (NC), NC+MS, miR135a over-expression (mi-miR135a), mimiR135a+MS, miR135a silencing (si-miR135a) and si-miR135a+MS groups. MS was induced by subjecting cells to cyclic stretch at 20% stretch for 4 h. After 24 h, levels of reactive oxygen species (ROS) were measured by DCFH-DA fluorescence intensity. Apoptosis was measured using annexin V-FITC/propidium iodide assay with flow cytometry. Inflammatory cytokine levels were determined by ELISA. Barrier integrity was determined using FITC-conjugated dextran assay. Expression levels of PI3K, p-PI3K, Akt, p-Akt, Bcl-2 and Bax were examined using western blotting. The interaction between miR135a and PHLPP2 was evaluated by dualluciferase reporter assay. Results: Our results showed that MS reduced cell numbers, increased the number of apoptotic cells, increased ROS, barrier dysfunction and inflammatory cytokines in HUVECs, and reduced p-PI3K and p-Akt expression; silencing of miR135a worsened MSinduced HUVEC injury. However, miR135a over-expression protected HUVECs against MSinduced increases in apoptotic cells, ROS, barrier dysfunction and inflammatory cytokines,
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Introduction
Mechanical ventilation (MV) is part of basic life support during general anesthesia as well as in critically ill patients with and without respiratory failure. However, MV itself has the potential to cause or worsen lung injury, which is known as ventilator-induced lung injury (VILI) [1] . Acute respiratory distress syndrome (ARDS) accounts for approximately one-third of intensive care unit admissions [2] and nearly all patients with ARDS require MV. Therefore, ARDS patients are usually at risk for VILI, and VILI has been definitively shown to contribute to mortality in patients with ARDS [3] . Although the precise pathogenic mechanism of VILI has not been completely clarified, several mechanisms have been proposed. Currently, inflammation and oxidative stress are accepted as important mechanisms in the pathogenesis of VILI, and thus inhibition of inflammation and/or oxidation is used for protection against VILI [4] . At the molecular level, G-protein-coupled receptors, stretchactivated ion channels, receptor tyrosine kinases, and other molecules are also involved in the pathogenesis of VILI [4, 5] . Increasing evidence indicates that loss of endothelial barrier function plays an important role in the development of VILI [6] . Mechanical stress may induce post-translational modifications to affect several important signaling pathways involved in VILI responses of the endothelium [6] .
MicroRNAs (miRNAs) are an evolutionarily conserved group of small non-coding RNA molecules (containing about 22 nucleotides) and play important roles in a variety of physiological and pathological processes [7] . Growing evidence indicates that dysregulation of miRNAs is closely associated with the pathogenesis of diseases including lung diseases [8] .
Vaporidi et al. investigated lung microRNA profiling in a mouse model of VILI and found that the expression of 65 miRNAs changed more than two-fold upon high tidal volume ventilation (HTVV; 40 mL/kg); antagonism of miR-21, an miRNA highly upregulated by HTVV, was able to preserve lung compliance and reduce alveolar-arterial oxygen difference and protein level in bronchoalveolar lavage [9] . In recent years, miR-135a has been extensively studied due to its controversial role in cancers. Mao et al. found that miR-135a was able to enhance cellular proliferation through regulation of PH domain leucine-rich repeat protein phosphatase (PHLPP) 2 and forkhead box O (FOXO) 1 in human bladder cancer [10] . In addition, miR135a is related to myocardial depression in sepsis [11] and anxiety-like behavior in the amygdala [12] . However, the role of miR-135a in VILI remains unclear.
In this study, the role of miR-135a in VILI and the relationship between miR-135a and PHLPP2 were investigated using MS in human umbilical vein endothelial cells (HUVECs).
Materials and Methods
Cell culture and groups HUVECs were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 1% streptomycin, and penicillin at 37°C with 5% CO 2 as described previously [13] . Adherent cells were characterized by their cobblestone morphology. Trypan blue staining showed higher than 95% cell viability. HUVECs were divided into 7 groups: blank control, negative control (NC), NC+mechanical stretch (MS), miR-135a over-expression (mi-miR-135a), mi-miR-135a+MS, miR-135a silencing (si-miR-135a) and si-miR-135a+MS groups. After various treatments, HUVECs (spindle-shaped) were observed under light microscopy and representative photographs were captured. HUVECs were counted in at least three fields for each group by two investigators blind to the study group, and the mean was calculated.
miRNA transfection and PHLPP2 silencing
HUVECs in the logarithmic growth phase were digested with trypsin and then counted. A singlecell suspension was prepared and cells were seeded into 6-well plates at a density of 5 × 10 5 cells/mL (1 mL/well), followed by incubation at 37°C with 5% CO 2 . HUVECs were grown to 70-80% confluence and transfected.
Cells were divided into blank control, NC, si-miR-135a and mi-miR-135a groups. In the blank control group, cells were maintained in serum-free Opti-mem® I (Gibco®, Waltham, MA, USA) medium (250 μL) without other treatment [14] . In the NC group, 5 μL negative control (about 100 pmol; 5'-CAGUACUUUUGUGUAGUACAA-3') was added to 245 μL serum-free Opti-mem medium; in the si-miR135a group, 5 μL miR-135a inhibitor (~100 pmol; 5'-UCACAUAGGAAUAAAAAGCCAUA-3') was added to 245 μL serum-free Opti-mem medium; in the mi-miR-135a group, 5 μL miR-135a mimic (~100 pmol; 5'-UAUGGCUUUUUAUUCCUAUGUGA-3') was added to 245 μL serum-free Opti-mem medium [15] . Cells were transfected in the presence of Lipofectamine® 2000 (Thermo Fisher Scientific, Carlsbad, CA, USA) at 37°C for 6 h. Then, the medium was removed and refreshed with normal medium. After 48 h, cells were harvested for experiments.
To investigate the role of PHLPP2 in MS-induced cell injury, PHLPP2 expression was silenced in HUVECs (sense: GACCUCUUCAGAUCGUUUAdTdT; anti-sense: UAAACGAUCUGAAGAGGUCdTdT). Western blotting and real-time PCR (Bio-Rad Laboratories, Hercules, CA, USA) were performed to confirm the silencing efficiency, and apoptotic cells following MS were detected after silencing of miR-135a and/or PHLPP2.
Real-time PCR
To investigate the efficiency of silencing and over-expression, real-time PCR was used to detect miR-135a and PHLPP2 expression. Total RNA was extracted from HUVECs with TRIzol® reagent (Invitrogen, Waltham, MA, USA) [16] . cDNA was generated from total RNA using a cDNA reverse transcription kit (Fermentas, Burlington, NC, USA) with specific primers for miR-135a (5' ACACTCCAGCTGGGTATGGCTTTTTATTCCT 3' The primer sequences were designed based on the cDNA sequences in GenBank. The reaction mixture included 2.0 µL cDNA, 0.2 µmol/L each paired primer, 200 µmol/L deoxynucleotide triphosphates, 1 U Taq DNA polymerase (Qiagen, Beijing, China) and 1× PCR buffer. The annealing temperature was set at 58-61°C and amplification was set at 40 cycles. The temperature range to detect the melting temperature of the PCR product was set at 60-95°C. The housekeeping gene GAPDH was used as an internal control for sample loading and normalization. To determine the relative quantitation of gene expression for both target and housekeeping genes, the comparative threshold cycle (Ct) method with arithmetic formulae (2 −ΔΔCt ) was used as described previously [17] . Messenger RNA levels were normalized relative to the housekeeping gene.
MS-induced HUVEC injury
In the MS groups, cells were subjected to MS to induce injury. In brief, HUVECs were plated onto collagen I-coated Bioflex culture plates (FlexCell International, Burlington, NC, USA) and grown to confluence. After 24 h, HUVECs were subjected to cyclic stretch as previously described [18] using the Flexcell FX-5000 tension system (FlexCell International). The pattern of cyclic stretch was set at a frequency of 30 cycles/min, with a stretch/relaxation relation of 1/1. Cyclic stretch was conducted at 20%. Unstretched control HUVECs were placed in the same incubator containing 5% CO 2 . Cyclic stretch was maintained for 4 h, and then cells were harvested and cultured for 24 h.
Flow cytometry of apoptotic cells
At 24 h after MS-induced cell injury, cell apoptosis was analyzed with the Annexin V-FITC/propidium iodide (PI) apoptosis detection kit (Beyotime Biotech, Jiangsu, China) following the manufacturer's instructions. Briefly, the cells were re-suspended and mixed in 500 μL binding buffer containing 5 μL Annexin 
Measurements of intracellular reactive oxygen species (ROS)
The intracellular ROS level was measured as a fluorescent product formed via the oxidation of DCFH-DA (Beyotime Biotech). Briefly, HUVECs were incubated with DCFH-DA (10 μmol/L) at 37°C for 30 min. DCFH-DA fluorescence intensity was detected at an excitation wavelength of 480 nm and emission wavelength of 525 nm by flow cytometry (Becton Dickinson) [19] .
Detection of inflammation-related factors by ELISA
The supernatant was collected by centrifugation at 2000 rpm for 10 min, and tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-1β were detected according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). Next, 2 μg/mL monoclonal anti-human mouse primary antibody against TNF-α, IL-6, or IL-1β, and the corresponding secondary antibodies conjugated to horseradish peroxidase (HRP) were used. Optical density (OD) was then measured in a microplate reader (MK3, Waltham, MA, USA) at a wavelength of 450 nm [20] . OD from the wells with blank sample (without primary antibody) was subtracted from each of the corresponding treatment samples.
Western blotting
HUVECs were homogenized in RIPA buffer (Beyotime). Proteins were extracted according to the manufacturer‫׳‬s instruction (Beyotime Biotech). After protein quantification, proteins (50 µg) were separated using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels (Mini-PROTEAN® 3 Dodeca™ Cell, Bio-Rad Laboratories) and subsequently transferred onto polyvinylidene fluoride membranes [21] . After blocking, the membranes were incubated with primary antibody against PI3K (1:1000; Ab189403, Abcam, Cambridge, MA, USA), p-PI3K (1:800; Ab182651, Abcam), Akt (1:1000; #9272, Cell Signaling Technology [CST], Danvers, MA, USA), p-Akt (1:1000; #9271, CST), Caspase-3 (1:500; Ab44976, Abcam), Bax (1:300; Sc-493, Santa Cruz Biotechnology, Dallas, TX, USA), Bcl2 (1:300; Sc-492, Santa Cruz Biotechnology), PHLPP2 (1:5000; Ab71973, Abcam), or GAPDH (1:2000; #5174, CST) at 4°C overnight, followed by incubation with goat anti-rabbit, donkey anti-goat, or goat anti-mouse HRP-conjugated secondary antibody (1:1000; Beyotime Biotech) for 2 h at room temperature. Immunoreactive proteins were visualized using the enhanced chemiluminescence Western blotting detection system (Millipore, Billerica, MA, USA) as described previously [22, 23] . Staining intensity of the bands was measured using a gel image analysis system (Tanon-5200, Shanghai, China).
Dual-luciferase reporter assay
A dual-luciferase reporter assay was used to investigate the interaction between PHLPP2 and miR-135a. The human PHLPP2 sequence was obtained from PUBMED, and analysis showed an miR-135a binding site in the 3' untranslated region (UTR) of PHLPP2 sequence (AAGCCAU). Then, the 3' UTR of PHLPP2 sequence was introduced to the site following Luc in the pGL3 luciferase vector (Promega, Madison, WI, USA). The sequence was identical to the target sequence, suggesting successful construction of the vector. Next, the single-cell suspension was added to 6-well plates at a density of 3 × 10 5 cells/well, followed by incubation at 37°C for 24 h. Cells were transfected in the presence of Lipofectamine® 2000 as mentioned above (NC, miR135a mimic and miR-135a inhibitor). Cells in each group were then treated with PHLPP2-UTR vector (1.5 µg in 250 µL serum-free Opti-mem) or blank vector. After transfection for 6 h, the medium was refreshed with complete medium, followed by incubation for another 42 h. The medium was then removed, and cells were washed with phosphate-buffered saline (PBS). After addition of 500 μL passive lysis buffer (PLB, Promega), cells were incubated at room temperature for 15 min. Then, 100 μL LARII and 20 μL lysed cell suspension were added to each well of a 96-well plate, and firefly luciferase activity was measured. After addition of 10 μL Stop&Glo, bacillus luciferase activity was measured. The ratio of firefly luciferase to bacillus luciferase activity was calculated. Determination of barrier integrity by measuring cell permeability HUVECs were divided into the above-mentioned 7 groups (blank control, NC, NC+MS, mi-miR-135a, mi-miR-135a+MS, si-miR-135a, and si-miR-135a+MS groups). Barrier integrity was determined by measuring cell permeability as described previously [24] . Briefly, at 24 h after transfection, the cells were seeded and grown to 95-100% confluence on collagen-coated 6-well BioFlex culture plates. Then, 4 kDa FITC-dextran (0.4 mg/mL) was directly added into the cell medium. Cells were subjected to MS-induced stress using the Flexcell FX-5000 tension system for 4 h or 8 h. The plate was then washed 3 times with PBS, and cells were lysed with 5% Triton X-100. Fluorescence intensity in the cell samples, which reflects the uptake of FITC-dextran, was measured with an Infinite M200 microplate reader (Tecan, Durham, NC, USA).
Statistical analysis
Statistical analysis was performed with SPSS version 20.0 for Windows. Data are expressed as the mean ± standard deviation. Comparisons were performed with one-way analysis of variance among groups, followed by post hoc analysis with Tukey's test. A value of P < 0.05 was considered statistically significant.
Results
Efficiency of silencing and over-expression
To investigate the role of miR-135a in the MSinduced injury in HUVECs, miR-135a was overexpressed or silenced in HUVECs which were then subjected to MS. miR-135a expression in these cells was detected by PCR to evaluate the efficiency of silencing and over-expression. We found that miR-135a expression after miR-135a silencing was reduced to about 1/4 of that in blank control group and NC group (P < 0.01), but increased significantly after over-expression (P < 0.01) as compared with the blank and NC groups (Fig. 1 A1, A2 ). Protein and mRNA expression of PHLPP2 were detected after silencing or over-expression of miR-135a to investigate whether PHLPP2 was a target of miR-135a. miR-135a over-expression significantly reduced protein and mRNA expression of PHLPP2, but miR-135a silencing markedly increased PHLPP2 expression at the protein and mRNA levels ( Fig. 1 B1, B2, B3) .
To investigate whether PHLPP2 mediates the effects of miR-135a, PHLPP2 was silenced in HUVECs and PHLPP2 expression was detected at the mRNA and protein levels. mRNA and protein expression were reduced significantly after PHLPP2 silencing as compared with the blank and NC groups (P < 0.01) (Fig. 1 C1, C2, C3) . 
Cell density
After culture for 24 h, the HUVECs were spindle-shaped and nearly 100% confluence was obtained (Fig. 2) . In the mi-miR-135a group, the cell density remained unchanged. However, in the si-miR-135a group, the cell density decreased significantly as compared with the blank and NC groups. In addition, after MS, the cell density decreased dramatically in the NC+MS, mi-miR-135a+MS, and si-miR-135a+MS groups, as compared with the corresponding untreated groups, and the cell number in the mi-miR-135a+MS group was markedly higher than in si-miR-135a+MS and NC+MS groups (P < 0.05).
Cell apoptosis
There is evidence that cyclic MS is able to induce apoptosis of alveolar type II cells [25] . Cell apoptosis was also evaluated after MS in the present study. As expected, MS significantly increased the number of HUVECs in early and later phases of apoptosis as compared with the corresponding untreated groups (P < 0.05). Moreover, silencing of miR-135a alone significantly increased the number of apoptotic cells as compared with the NC and blank groups (P < 0.05) (Fig. 3 A, B) . The number of apoptotic cells in the mi-miR-135a+MS group was markedly lower than in the NC+MS and si-miR-135a+MS groups (P < 0.01), and a significant difference was also observed between the NC+MS and si-miR-135a+MS groups (P < 0.05) (Fig. 3 A, B) . Of note, silencing of miR-135a alone also dramatically increased the number of apoptotic HUVECs as compared with the NC and blank groups (P < 0.05) (Fig. 3  A, B) .
We also determined Bax, Bcl-2 and caspase protein expression in HUVECs of the different groups. Our results showed that silencing of miR-135a significantly increased Bax and caspase-3 expression but reduced Bcl-2 expression as compared with the NC and blank groups (P < 0.05) (Fig. 4 A, B) . As expected, MS significantly increased Bax and caspase-3 expression and markedly reduced Bcl-2 expression in HUVECs as compared with the corresponding (Fig. 4 A, B) . Furthermore, Bax and caspase-3 expression in the mi-miR-135a+MS group were markedly lower than in the NC+MS and simiR-135a+MS groups, but Bcl-2 expression in the simiR-135a+MS group was significantly higher than in latter two groups (P < 0.05) (Fig. 4 A, B) . These findings were consistent with the increase in the number of apoptotic cells after MS.
In addition, apoptotic cells were detected after silencing of PHLPP2 and MS. MS also increased the number of apoptotic cells in HUVECs with PHLPP2 silencing, but the number of apoptotic cells was significantly lower than in the MS group (P < 0.01; Fig.  3 C, D) . Moreover, in the presence of simultaneous silencing of miR-135a and PHLPP2, the number of apoptotic cells after MS was markedly higher than after silencing of PHLPP2, but significantly lower than after silencing of miR-135a (P < 0.05; Fig.  3 C, D) . Western blotting also showed that silencing of PHLPP2 reduced the expression of Bax and caspase-3, but increased Bcl-2 expression in HUVECs after MS as compared with the MS and si-miR-135a+MS groups (P < 0.05) (Fig. 4 D, E) . After silencing of both miR-135a and PHLPP2, protein expression of Bax and caspase-3 were lower than in the si-miR-135a+MS group but higher than in the si-PHLPP2+MS group (P < 0.05) (Fig. 4 D, E) .
Expression of PI3K, p-PI3K, Akt, and p-Akt
There is evidence that the PI3K/Akt signaling pathway is involved in the development of VILI [26] and Akt is also a target of PHLPP2 [27] . In the present study, we further detected the protein expression of PI3k and Akt in HUVECs after MS. Our results show that MS significantly inhibited the activation of the PI3K/Akt signaling pathway (reduced expression of p-PI3K and p-Akt, vs blank and NC groups) and silencing of miR-135a further decreased the expression of p-PI3K and p-Akt (P < 0.05, si-miR-135a+MS vs NC+MS group) (Fig. 4 A,  C) . However, miR-135a over-expression increased the expression of p-PI3K and p-Akt as compared with the NC+MS (P < 0.05) and si-miR-135a+MS groups (P < 0.01) (Fig. 4 A, C) . Of note, silencing of miR-135a alone also markedly inhibited the activation of the PI3K/Akt pathway (P < 0.05) (Fig. 4 A, C) . In addition, silencing of PHLPP2 increased the protein expression of p-Akt and p-PI3K in HUVECs after MS as compared with the MS group (Fig. 4 D,  F) . In the presence of silencing of both PHLPP2 and miR-135a, p-Akt and p-PI3K protein expression in HUVECs after MS increased significantly as compared with the si-miR135a+MS group, but decreased significantly as compared with the si-PHLPP2+MS group (P < 0.05) (Fig. 4D, F) .
ROS
There is evidence that MV may cause oxidative stress in lung cells [28] . In our study, in vitro MS also significantly increased ROS production in HUVECs as compared with the corresponding untreated groups (P < 0.05) (Fig. 5) . In addition, ROS in the mi-miR-135a+MS group were markedly lower than in the NC+MS and si-miR135a+MS groups (P < 0.01), and there was a marked difference between the NC+MS and si-miR-135a+MS groups (P <0.05) (Fig. 5) . Furthermore, silencing of miR-135a alone also dramatically increased the production of ROS in HUVECs as compared with the NC and blank control groups (P < 0.05) (Fig. 5) .
Barrier integrity
We measured the influence of miR135a on MS-induced barrier integrity in HUVECs using the FITC-dextran assay. MS for 4 h induced obvious barrier dysfunction (Fig. 6 A) . Moreover, MS for 8 h induced greater reduction of barrier integrity compared with treatment for 4 h (Fig. 6  B) . Notably, administration of an miR-135a mimic significantly reduced the MS-induced barrier dysfunction in both experiments (4 h and 8 h) (Fig. 6 A, B) . By contrast, knockdown of miR-135a further decreased barrier dysfunction induced by MS (Fig. 6 A,  B) .
Inflammatory cytokines
Studies have shown that MV may induce inflammation in lung cells [29, 30] . In our study, inflammatory cytokines (TNF-α, IL-1β, and IL-6) were detected in HUVECs after in vitro MS. As shown in Fig. 7, in vitro MS significantly increased these inflammatory cytokines as compared with the corresponding untreated groups (P < 0.05). In addition, the levels of inflammatory cytokines secreted by HUVECs in the mimiR-135a+MS group were markedly lower than in the NC+MS and si-miR-135a+MS groups (P < 0.05) and there was a marked difference between the NC+MS and simiR-135a+MS groups (P < 0.05) (Fig. 7) . Of note, silencing of miR-135a alone also dramatically increased the levels of these inflammatory cytokines in HUVECs as compared with the NC and blank control groups (P < 0.05) (Fig. 7) .
Dual-luciferase reporter assay
In the presence of blank pGL3 luciferase vector, the luciferase activity ratio was comparable among the three groups (P>0.05; Fig. 8 A) . However, after introduction of 3' UTR of PHLPP2 into this vector, miR-135a mimic significantly reduced the luciferase activity ratio, but miR-135a inhibitor markedly increased the luciferase activity ratio as compared with the NC group (Fig. 8 B) . This suggests that miR-135a is able to interact with PHLPP2.
Discussion
In this study, we investigated the effects of miR-135a on MS-induced cell injury. We found that (1) MS increased apoptosis in HUVECs, production of inflammatory cytokines and generation of ROS in vitro; (2) silencing of miR-135a decreased MSinduced injury of HUVECs, whereas miR135a over-expression had the opposite effect; and (3) the protective effects of miR-135a may be related to its inhibition of PHLPP2 and subsequent activation of the PI3K/Akt signaling pathway.
A number of molecular mechanisms may contribute to acute lung injury [31] [32] [33] [34] . To date, miRNA profile has been the focus in biological studies related to acute lung injury. Although the role of miR-135a has been extensively investigated in cancer, little is known about its role in VILI. In this study, we investigated the role of miR-135a in VILI in vitro by focusing on inflammation, oxidative stress, and apoptosis, which are 
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Cellular Physiology and Biochemistry three critical molecular mechanisms involved in the pathogenesis of VILI. It is clear that knockdown of miR-135a significantly increased apoptosis under MS-induced stress (Fig.  3) . This result was supported by data showing significant upregulation of pro-apoptotic factors Bax and caspase-3 (Fig. 4) in cells with miR-135a knockdown; overexpression of miR-135a had the opposite effect. To provide more evidence about function of miR135a, we measured intracellular ROS content (Fig. 5) , barrier integrity (Fig. 6) , and the levels of three pro-inflammatory cytokines (TNF-a, IL-6, and IL-1b) (Fig. 7) . Under MSinduced stress, knockdown of miR-135a further triggered an increase in ROS content and enhanced concentrations of TNF-a, IL-6, and IL-1b, whereas overexpression of miR-135a suppressed ROS content and decreased TNF-a, IL-6, and IL-1b levels. Based on these results, we considered that miR-135a protects against MS-induced stress in cells. Of note, it has been shown that inhibition of miR-135a was able to protect A549 cells from LPS-induced apoptosis by targeting Bcl-2 [35] and over-expression of miR-135a blocked Bcl-2 protein and enhanced H 2 O 2 -induced apoptosis in H9c2 cells [36] ; upregulation of miR-135a could aggravate sepsis-induced inflammation in BALB/c mice [11] . These discrepancies might be attributed to differences in cell types. PHLPPs are a class of potent inhibitor of Aky that dephosphorylate Akt isoforms at Ser473 and have been intensively investigated in cancer. Due to this feature, PHLPPs critically regulate cellular homeostasis, and the dysregulation of PHLPPs is tightly associated with various pathophysiological changes [37] . In this study, we found that PHLPP2 silencing markedly inhibited MS-induced apoptosis in HUVECs. Findings from the dual-luciferase reporter assay confirmed that miR-135a could interact with PHLPP2 (Fig. 8) . These results indicate that miR-135a suppressed PHLPP2 protein level in HUVECs under MS-induced stress. Since PHLPP2 dephosphorylates Akt at Ser473, the reduced PHLPP2 in miR-135a-overexpressed HUVECs would activate the Akt signaling pathway. It should be noted that the Akt pathway is a classical pro-survival signaling pathway in cells. Thus, we believe that the pro-survival action of miR-135a is at least partially mediated by PHLPP2.
Interestingly, PHLPP2 participates in the biological functions of many miRNAs. In a previous study, Mao et al. found that miR-135a enhanced cellular proliferation through targeting PHLPP2 and FOXO1 in human bladder cancer [10] . Moreover, PHLPP2 seemed to be a crucial mediator of the regulatory effects of miR-32 [38] , miR-760 [39] , miR-181a [40] , miR27a [41] , and miR-938 [42] on cell proliferation and migration. Our results provide the first evidence that PHLPP2 may be the direct target of miR-135a and contributes to the influence of miR-135a on HUVEC survival under MS-induced stress. However, it is unlikely that a single phosphatase PHLPP2 could be responsible for all the endothelial derangements associated with VILI. In this case, the miR-135a-PHLPP2 pathway may be only one of several regulatory mechanisms involved in VILI-associated endothelial dysfunction. Further investigations focusing on the roles of miRNAs and their targets in VILI-associated endothelial dysfunction are warranted.
The preservation of vascular endothelial cell barrier integrity is critical to vessel homeostasis, and barrier dysfunction is a key feature of acute lung injury [43] and VILI [6] . The reduced endothelial barrier integrity in VILI is due to mechanical ventilation at high tidal volume and the associated pulmonary capillary leakage and acute lung inflammation. SC5b-9, a measure of complement activation, causes an increase in rat pulmonary microvascular permeability by inducing activation of RhoA and subsequent phosphorylation of myosin light chain and contraction of endothelial cells [44] . Caveolin-1, a key regulator of pulmonary endothelial barrier function, is required for MS-induced pulmonary edema and endothelial hyperpermeability in vitro and in vivo [45] . To explore the role of miR-135a in pulmonary alveolar barrier function, we further studied the effect of miR-135a overexpression and knockdown on endothelial barrier properties in vitro. As expected, our results clearly showed that miR-135a protected against MS-induced barrier dysfunction (Fig. 6) . We believe that this protective effect of miR-135a on endothelial barrier integrity may contribute to the beneficial actions of miR-135a in VILI.
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There is evidence that Akt, PKC, the Ras-Raf-MEK-ERK pathway, AGC kinase family members, and other molecules may be the targets of PHLPPs [37] . In addition, studies indicate that PHLPP1 and PHLPP2 may both serve as tumor suppressors, largely attributed to PHLPP-dependent suppression of pro-survival signaling, such as through the PI3K/ Akt signaling pathway [37, 46] . The phosphatidylinositol-3 kinase (PI3K) signaling pathway plays an essential role in some physiological and cellular processes including cell proliferation, growth, survival, migration, and metabolism [47] . Studies have shown that the PI3K signaling pathway is involved in the pathogenesis of some respiratory diseases and may serve as a target in the treatment of these diseases [47] . The role of the PI3K pathway in the pathogenesis of VILI is still controversial [48] . Shu et al. found that an inhibitor of IκB kinase (IKK16) may attenuate VILI via activation of the PI3K/Akt signaling pathway in Sprague-Dawley rats [49] . In a study by Faller et al., results showed that protection of isoflurane during MV was accompanied by substantial phosphorylation of Akt protein and inhibition of PI3K/Akt signaling before MV completely reversed the lung-protective effects of isoflurane treatment in C57BL/6N mice [50] . However, in earlier studies, results indicated that PI3K-γ in resident lung cells mediated part of the alveolar edema induced by high-stress ventilation [51] and silencing of PI3K-γ seemed to attenuate functional and morphological consequences of VILI [52] . In addition, pretreatment with a PI3K inhibitor (LY-294002) significantly attenuated VILI, whereas an Akt inhibitor markedly reduced VILI in isolated lungs [53] . Thus, we further investigated the expression of target molecules of PHLPP2 in the PI3K/Akt signaling pathway. Our results showed that MS could inhibit the PI3K/ Akt signaling pathway (reduction in p-PI3K and p-Akt expression) and silencing of miR135a further reduced p-PI3K and p-Akt expression in HUVECs. However, miR-135a overexpression significantly activated the PI3K/Akt signaling pathway (characterized by marked increase in p-PI3K and p-Akt expression) (Fig. 4) , which was accompanied by improvement of HUVEC injury. Furthermore, silencing of PHLPP2 increased p-Akt and p-PI3K protein expression, but simultaneous silencing of miR-135a compromised activation of the PI3K/ Akt signaling pathway after PHLPP2 silencing in HUVECs (Fig. 4) .
Several possible limitations of this study should be considered. After PHLPP2 silencing, we detected apoptotic cells following MS, but whether PHLPP2 silencing alone affects the apoptosis of HUVECs was not investigated, and other parameters were not measured after PHLPP2 silencing in HUVECs following MS. In addition, this study was conducted in HUVECs, and pulmonary endothelial cells are more representative of cells involved in VILI [54, 55] . Thus, our results need to be confirmed in pulmonary endothelial cells and in animal models in the future.
Taken together, our findings suggest that miR-135a may inhibit PHLPP2 to activate the PI3K/Akt signaling pathway, exerting protective effects on MS-induced injury to HUVECs.
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